BE-SMART (Basal Early Strategies to Maximize HbA1c Reduction with Oral Therapy): Expert Opinion.
Basal insulin
Degludec
Detemir
Glargine
Hypoglycemia
Titration
Type 2 diabetes mellitus
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
19
03
2019
pubmed:
19
5
2019
medline:
19
5
2019
entrez:
19
5
2019
Statut:
ppublish
Résumé
The past three decades have seen a quadruple rise in the number of people affected by diabetes mellitus worldwide, with the disease being the ninth major cause of mortality. Type 2 diabetes mellitus (T2DM) often remains undiagnosed for several years due to its asymptomatic nature during the initial stages. In India, 70% of diagnosed diabetes cases remain uncontrolled. Current guidelines endorse the initiation of insulin early in the course of the disease, specifically in patients with HbA1c > 10%, as the use of oral agents alone is unlikely to achieve glycemic targets. Early insulin initiation and optimization of glycemic control using insulin titration algorithms and patient empowerment can facilitate the effective management of uncontrolled diabetes. Early glucose control has sustained benefits in people with diabetes. However, insulin initiation, dose adjustment, and the need to repeatedly assess blood glucose levels are often perplexing for both physicians and patients, and there are misconceptions and concerns regarding its use. Hence, an early transition to insulin and ideal intensification of treatment may aid in delaying the onset of diabetes complications. This opinion statement was formulated by an expert panel on the basis of existing guidelines, clinical experience, and economic and cultural contexts. The statement stresses the timely and appropriate use of basal insulin in T2DM. It focuses on the seven vital Ts-treatment initiation, timing of administration, transportation and storage, technique of administration, targets for titration, tablets, and tools for monitoring.Funding: Sanofi.
Identifiants
pubmed: 31102253
doi: 10.1007/s13300-019-0629-z
pii: 10.1007/s13300-019-0629-z
pmc: PMC6612329
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1189-1204Références
J Korean Med Sci. 2014 Jan;29(1):90-7
pubmed: 24431911
Diabetes Obes Metab. 2013 Aug;15(8):690-700
pubmed: 23253563
Arch Med Sci. 2015 Aug 12;11(4):840-8
pubmed: 26322096
N Engl J Med. 2012 Jul 26;367(4):319-28
pubmed: 22686416
J Multidiscip Healthc. 2014 Jul 02;7:267-82
pubmed: 25061317
Diabetes Care. 2011 Oct;34(10):2333-5
pubmed: 21949226
Diabetes Care. 2003 Jan;26 Suppl 1:S28-32
pubmed: 12502617
Int J Clin Exp Pathol. 2015 Nov 01;8(11):14141-50
pubmed: 26823727
Diabetes Obes Metab. 2018 Mar;20(3):488-496
pubmed: 29053215
Mayo Clin Proc. 2016 Sep;91(9):1231-55
pubmed: 27594187
Diabetol Metab Syndr. 2018 Apr 3;10:26
pubmed: 29636825
Indian J Endocrinol Metab. 2013 Jul;17(4):594-601
pubmed: 23961474
Nat Rev Endocrinol. 2018 Feb;14(2):88-98
pubmed: 29219149
Diabetes Care. 2013 Apr;36(4):858-64
pubmed: 23340894
Diabet Med. 2006 Jul;23(7):736-42
pubmed: 16842477
Indian J Endocrinol Metab. 2016 May-Jun;20(3):408-11
pubmed: 27186563
Eur Endocrinol. 2018 May;14(Suppl1):2-9
pubmed: 30034546
Diabetes Care. 2002 Dec;25(12):2133-40
pubmed: 12453950
Vasc Health Risk Manag. 2008;4(6):1189-95
pubmed: 19337532
J Diabetes Metab Disord. 2013 Mar 05;12(1):14
pubmed: 23497559
Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S432-3
pubmed: 23565455
MedGenMed. 2006 Nov 15;8(4):34
pubmed: 17415316
Indian J Endocrinol Metab. 2015 Sep-Oct;19(5):577-96
pubmed: 26425465
Diabetes Care. 2005 Feb;28(2):419-20
pubmed: 15677803
Diabetes Obes Metab. 2014 Mar;16(3):193-205
pubmed: 23668598
Drug Saf. 2004;27(12):841-56
pubmed: 15366973
Indian J Endocrinol Metab. 2017 May-Jun;21(3):482-483
pubmed: 28553610
J Clin Endocrinol Metab. 2010 May;95(5):2163-71
pubmed: 20237169
J Assoc Physicians India. 2014 Jul;62(7 Suppl):49-54
pubmed: 25668937
Indian J Endocrinol Metab. 2016 Jan-Feb;20(1):22-31
pubmed: 26904465
Diabetes Care. 2013 Aug;36 Suppl 2:S259-63
pubmed: 23882055
BMJ Open Diabetes Res Care. 2018 Jul 10;6(1):e000519
pubmed: 30023075
PLoS One. 2014 Mar 10;9(3):e87799
pubmed: 24614911
J Assoc Physicians India. 2011 Apr;59 Suppl:8-12
pubmed: 21818992
Diabetes Ther. 2019 Apr;10(2):341-366
pubmed: 30815830
Indian J Endocrinol Metab. 2017 Jul-Aug;21(4):600-617
pubmed: 28670547
Diabetes Care. 2005 Jun;28(6):1282-8
pubmed: 15920040
Clin Diabetes. 2019 Jan;37(1):11-34
pubmed: 30705493
BMJ Open Diabetes Res Care. 2015 Jun 16;3(1):e000108
pubmed: 26113983
J Diabetes Complications. 2015 Mar;29(2):295-301
pubmed: 25536866
Curr Vasc Pharmacol. 2009 Jan;7(1):68-74
pubmed: 19149642
Diabetes Technol Ther. 2013 Sep;15(9):776-85
pubmed: 23786228